MONTORSI, FRANCESCO
 Distribuzione geografica
Continente #
EU - Europa 9.883
NA - Nord America 6.872
AS - Asia 3.281
AF - Africa 149
OC - Oceania 73
SA - Sud America 65
Continente sconosciuto - Info sul continente non disponibili 10
Totale 20.333
Nazione #
US - Stati Uniti d'America 6.742
SE - Svezia 4.378
RU - Federazione Russa 2.185
SG - Singapore 1.908
IT - Italia 1.715
CN - Cina 554
FI - Finlandia 494
IE - Irlanda 316
IN - India 295
DE - Germania 265
ID - Indonesia 126
GB - Regno Unito 110
JP - Giappone 93
NL - Olanda 83
CA - Canada 79
FR - Francia 74
TR - Turchia 63
IR - Iran 62
AU - Australia 59
ES - Italia 48
NG - Nigeria 47
BR - Brasile 45
MX - Messico 41
UA - Ucraina 40
PL - Polonia 30
HK - Hong Kong 29
EG - Egitto 20
TW - Taiwan 20
BE - Belgio 19
PK - Pakistan 18
GR - Grecia 17
CH - Svizzera 16
DZ - Algeria 14
CZ - Repubblica Ceca 13
IL - Israele 13
TZ - Tanzania 13
KR - Corea 12
NO - Norvegia 12
PH - Filippine 12
VN - Vietnam 12
AT - Austria 11
TN - Tunisia 11
EU - Europa 9
IQ - Iraq 9
MY - Malesia 9
NZ - Nuova Zelanda 9
SA - Arabia Saudita 9
GH - Ghana 8
HR - Croazia 8
KE - Kenya 8
TH - Thailandia 8
BD - Bangladesh 7
BG - Bulgaria 7
CO - Colombia 7
PT - Portogallo 7
LT - Lituania 6
CL - Cile 5
CM - Camerun 5
HU - Ungheria 5
PG - Papua Nuova Guinea 5
LK - Sri Lanka 4
MW - Malawi 4
NP - Nepal 4
PA - Panama 4
RO - Romania 4
GN - Guinea 3
JO - Giordania 3
MK - Macedonia 3
OM - Oman 3
SI - Slovenia 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
CU - Cuba 2
DK - Danimarca 2
GM - Gambi 2
JM - Giamaica 2
KW - Kuwait 2
LR - Liberia 2
LU - Lussemburgo 2
LV - Lettonia 2
MA - Marocco 2
RE - Reunion 2
SK - Slovacchia (Repubblica Slovacca) 2
ZA - Sudafrica 2
ZM - Zambia 2
AL - Albania 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BF - Burkina Faso 1
BJ - Benin 1
EC - Ecuador 1
GT - Guatemala 1
HN - Honduras 1
LY - Libia 1
ME - Montenegro 1
MT - Malta 1
MU - Mauritius 1
Totale 20.328
Città #
Lawrence 2.114
Princeton 2.107
Singapore 1.067
Moscow 1.054
Ashburn 544
Helsinki 484
Milan 443
New York 423
Dublin 312
Shanghai 288
Boardman 218
Pune 154
Rome 114
Seattle 73
Los Angeles 63
Washington 63
Hanover 43
Borås 39
Florence 38
Turin 38
Bologna 31
Paris 28
Sydney 27
Delhi 25
Istanbul 22
Bengaluru 21
Central 20
Naples 19
Palermo 19
Bari 18
Genoa 18
Mumbai 18
Pekanbaru 18
Pisa 18
Lagos 17
London 17
Makassar 17
Jakarta 16
Oldenburg 16
Amsterdam 15
St Petersburg 15
Azzano San Paolo 14
Council Bluffs 14
Tokyo 14
Ankara 13
Dar es Salaam 13
Hyderabad 13
Redwood City 13
Chicago 12
Monza 12
Pescara 12
Chennai 11
Nuremberg 11
Perugia 11
Rockville 11
Abuja 10
Ho Chi Minh City 10
Tel Aviv 10
Vaprio d'Adda 10
Athens 9
Coslada 9
Iztapalapa 9
Monterrey 9
Montreal 9
Padova 9
Prague 9
Rozzano 9
San Jose 9
Semarang 9
Tehran 9
Toronto 9
Vienna 9
Accra 8
Berlin 8
Brisbane 8
Cairo 8
Catania 8
Ferrara 8
Melbourne 8
Modena 8
Mountain View 8
Pavia 8
Perth 8
Santa Maria 8
West Jordan 8
Andover 7
Bergamo 7
Brooklyn 7
Bursa 7
Corinth 7
Kaohsiung City 7
Katsina 7
Kebumen Satu 7
Miami 7
Naaldwijk 7
Parma 7
São Paulo 7
Bandung 6
Bangkok 6
Barcelona 6
Totale 10.631
Nome #
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection 643
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers 346
Benign Prostatic Hyperplasia and Its Aetiologies 346
Women's sexual dysfunction: a pathophysiological review 231
Worldwide Temporal Trends in Penile Length: A Systematic Review and Meta-Analysis 82
Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: Results of a cross-sectional study 79
Organic vs. Psychogenic? The Manichean Diagnosis in Sexual Medicine 75
Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series 56
(11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms 54
Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum 51
A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation 51
Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. 49
FATTORI PREDITTIVI DI LINFORREA DOPO PROSTATECTOMIA RADICALE E LINFOADENECTOMIA PELVICA 47
Long-term safety and tolerability of thdalafil in the treatment of erectile dysfunction 46
Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. 44
11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy 41
Prediction of Sexual Function After Radical Prostatectomy 40
Nasal congestion after visual sexual stimulation with and without sildenafil (Viagra (R)): a randomized placebo-controlled study 35
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies 34
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series 34
Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores 33
Sildenafil taken at bedtime significantly increases nocturnal erections: Results of a placebo-controlled study 33
Quantitative sensory testing of peripheral thresholds in patients with lifelong premature ejaculation: a case-controlled study 33
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis 32
QUALI SONO I PAZIENTI A RISCHIO DI RECIDIVA BIOCHIMICA DI CARCINOMA PROSTATICO OLTRE I 10 ANNI DI FOLLOW-UP DOPO PROSTATECTOMIA RADICALE? 32
Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease 31
Pelvic lymph node dissection in prostate cancer 31
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 31
Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy 31
A comparative review of apomorphine formulations for erectile dysfunction - Recommendations for use in the elderly 30
Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer 30
Infertility as a Proxy of Men's Health: Still a long way to go 30
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma 29
Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy 29
Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients 29
Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient 29
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 29
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis 28
Rates and predictors of postoperative complications after Holmium laser enucleation of the prostate (HoLEP) at a high-volume center 28
The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy 27
ELETTROSTIMOLAZIONE INTRAOPERATORIA DEI NERVI CAVERNOSI CON ELETTRODI IMPIANTABILI 27
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? 26
When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool 26
PRESENTAZIONE CLINICA DELLA INDURATIO PENIS PLASTICA NEI PAZIENTI AL DI SOTTO DEI 40 ANNI 26
Radical prostatectomy for incidental (stage t1a-t1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence 26
Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography 26
A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma 26
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 26
Correlation among isolated teratozoospermia, sperm DNA fragmentation and markers of systemic inflammation in primary infertile men 26
Medications mostly associated with priapism events: assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries 25
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma 25
Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation 25
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––A large, retrospective, single-center study 25
Does sildenafil enhance quality of nocturnal erections in healthy young men? A NPT-RigiScan (TM) study 25
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? 25
How to Select the Optimal Candidates for Renal Mass Biopsy 25
Acute Kidney Injury at Hospital Admission for SARS-CoV-2 Infection as a Marker of Poor Prognosis: Clinical Implications for Triage Risk Stratification 25
Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases 24
Second international conference on management of erectile dysfunction: New perspectives on treatment 24
Choosing the Best Candidates for Penile Rehabilitation after Bilateral Nerve-Sparing Radical Prostatectomy 24
Biopsy Core Number Represents One of Foremost Predictors of Clinically Significant Gleason Sum Upgrading in Patients With Low-risk Prostate Cancer 24
PICCOLE MASSE RENALI: SORVEGLIANZA ATTIVA VS. NEFRECTOMIA 24
Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization 24
68Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications 24
Aging, inflammation and DNA damage in the somatic testicular niche with idiopathic germ cell aplasia 24
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 23
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis 23
Testosterone in males with COVID-19: A twelve-month cohort study 23
Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial 23
L'INVASIONE ESCLUSIVA DEL COLLO VESCICALE DA CARCINOMA PROSTATICO NON DOVREBBE ESSERE CONSIDERATA COME STADIO PT4 23
Clinical Profile of Young Patients with Erectile Dysfunction: Preliminary Findings of a Real-life Cross-sectional Study 23
Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer 23
Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy 23
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma 23
Severely low testosterone in males with COVID-19: a case-control study 23
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial 23
Leiomyoadenomatoid tumours of the epididymis: A new case report and review of the literature 23
Risk of health status worsening in primary infertile men: A prospective 10-year follow-up study 23
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 23
A Plea for Economically Sustainable Evidence-based Guidelines 23
A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer 22
A global approach to improving penile cancer care 22
Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation 22
Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? 22
A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation 22
Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience 22
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 22
Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy 22
Erectile function after focal therapy for localized prostate cancer: a systematic review 22
Can We Rely Solely on the International Prostate Symptoms Score to Investigate Storage Symptoms in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement? Findings from a Cross-sectional Study 22
Combined plasma levels of IL-10 and testosterone, but not soluble HLA-G5, predict the risk of death in COVID-19 patients 21
TRANSRECTAL MICROWAVE HYPERTHERMIA FOR ADVANCED PROSTATE-CANCER - LONG-TERM CLINICAL-RESULTS 21
11C-CHOLINE-POSITRON EMISSION TOMOGRAPHY/ COMPUTERISED TOMOGRAPHY FOR PREOPERATIVE LYMPH- NODE STAGING IN INTERMEDIATE-RISK AND HIGH-RISK PROSTATE CANCER: COMPARISON WITH CLINICAL STAGING NOMOGRAMS 21
[11C]CHOLINE PET/CT SCAN PREDICTS SURVIVAL IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY 21
A risk calculator predicting recurrence in lymph node metastatic penile cancer 21
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 21
Infertile Men Have Higher Prostate-specific Antigen Values than Fertile Individuals of Comparable Age 21
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 21
Perioperative Outcomes of Open, Laparoscopic, and Robotic Partial Nephrectomy: A Prospective Multicenter Observational Study (The RECORd 2 Project) 21
Endoplasmic reticulum oxidoreductase 1 alpha modulates prostate cancer hallmarks 21
Totale 4.391
Categoria #
all - tutte 380.767
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 380.767


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020137 73 3 2 9 39 0 0 1 7 3 0 0
2020/2021174 0 0 11 3 2 124 8 2 8 6 8 2
2021/20221.270 1 57 30 577 61 63 90 75 42 69 55 150
2022/202310.100 4.860 1.735 598 119 68 1.009 434 605 272 96 149 155
2023/20245.155 233 279 399 356 413 922 292 508 90 380 562 721
2024/20254.115 4.115 0 0 0 0 0 0 0 0 0 0 0
Totale 21.393